<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="200249">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00483431</url>
  </required_header>
  <id_info>
    <org_study_id>MEC 07-3-014</org_study_id>
    <nct_id>NCT00483431</nct_id>
  </id_info>
  <brief_title>Dose-Finding Study for Vitamin K2 in Human Volunteers</brief_title>
  <official_title>Dose-Finding Study for Vitamin K2 in Human Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Earlier studies have shown that high vitamin K-intake leads to improved bone and vascular
      health by increased carboxylation of Gla-proteins in these tissues. From all K-vitamins,
      menaquinone-7 (MK-7) has been identified as the most effective cofactor for the
      carboxylation reaction of Gla-proteins such as osteocalcin and matrix-gla protein. The
      question remains which dosage of MK-7 leads to optimal carboxylation levels of these
      proteins.

      The primary objective of this double-blind randomized intervention study is to establish the
      optimal dose of MK-7 for carboxylation of the vitamin K-dependent proteins osteocalcin in
      bone and matrix-gla protein in the vessel wall. The optimal dose will be the concentration
      at which osteocalcin and matrix-gla protein are &gt; 90% in the active (=carboxylated) form.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>undercarboxylated osteocalcin</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>carboxylated osteocalcin</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>undercarboxylated matrix-gla protein</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>carboxylated matrix-gla protein</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Vitamin K-Status</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mcg Vitamin K</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mcg Vitamin K</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>45 mcg Vitamin K</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>90 mcg Vitamin K</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>180 mcg Vitamin K</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>360 mcg Vitamin K for 3 months daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>no vitamin K</intervention_name>
    <description>no vitamin K</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>10 mcg Vitamin K for 3 months daily</intervention_name>
    <description>10 mcg Vitamin K for 3 months daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>20 mcg Vitamin K for 3 months daily</intervention_name>
    <description>20 mcg Vitamin K for 3 months daily</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>45 mcg Vitamin K for 3 months daily</intervention_name>
    <description>45 mcg Vitamin K for 3 months daily</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>90 mcg Vitamin K for 3 months daily</intervention_name>
    <description>90 mcg Vitamin K for 3 months daily</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>180 mcg Vitamin K for 3 months daily</intervention_name>
    <description>180 mcg Vitamin K for 3 months daily</description>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>360 mcg Vitamin K for 3 months daily</intervention_name>
    <description>360 mcg Vitamin K for 3 months daily</description>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female adults between 18 and 45 years of age.

          -  Subjects of normal body weight and height according to BMI &lt; 30

          -  Subject has given written consent to take part in the study

        Exclusion Criteria:

          -  Subjects with (a history of) metabolic or gastrointestinal disease

          -  Subject with (a history of) soy allergy

          -  Subjects using vitamin supplements containing vitamin K

          -  Subjects presenting chronic inflammatory diseases

          -  Subjects receiving systemic treatment or topical treatment likely to interfere with
             evaluation of the study parameters

          -  Subjects receiving corticoÏŠd treatment

          -  Subjects using oral anticoagulants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cees Vermeer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VitaK BV / University of Maastricht</name>
      <address>
        <city>Maastricht</city>
        <state>PO Box 616</state>
        <zip>6200 MD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <lastchanged_date>March 9, 2009</lastchanged_date>
  <firstreceived_date>June 6, 2007</firstreceived_date>
  <responsible_party>
    <name_title>Dr.C.Vermeer</name_title>
    <organization>VitaK BV</organization>
  </responsible_party>
  <keyword>vitamin K2</keyword>
  <keyword>dosis-response</keyword>
  <keyword>osteocalcin</keyword>
  <keyword>matrix-gla protein</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Vitamin K 2</mesh_term>
    <mesh_term>Vitamin MK 7</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
